Remind me
Redondo Beach, California,finding results for patients with COVID-19 The U. S. Food and Drug Administration (FDA) recently approved an application for a new experimental drug from Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) that opens the door for Cardiol to conduct his Phase II/III trial, designed through leading inflammatory center disease experts, who will check the cardioprotective properties of cannabidiol (CBD) for patients with COVID-19 with a history or threat points of cardiovascular disease (CVD).
Heart and COVID
The U. S. Centers for Disease Control(CDC) identify pre-existing severe central disease as a major threat to patients with COVID-19. The CDC provided case awareness in the United States through May and found that 45% of hospitalized patients had underlying conditions. , with cardiovascular disease the maximum is not unusual at 32%. The European Society of Cardiology notes that the body’s inflammatory reaction to COVID-19 viral infection can tighten the cardiovascular formula and warns that “people with a central disease, such as central insufficiency, dilate cardiomyopathy, the complex bureaucracy of right ventricle arrhythmopathy and patients with congenital cyanotic center disease are the ultimate threat. “
To be clear, cardiovascular disease does not increase the chances of becoming infected, but increase the threat of serious headaches due to infection. COVID was originally thought to be primarily a respiratory disease, but the link to central disease requires the clinical network to identify exactly the nature of this link and propose remedies that may result for these patients.
Potential cardiol therapy
Cardiol Therapeutics is a Canadian company founded and run through a team of cardiovascular disease experts. Chief Executive David Elsley founded Vasogen, Inc. in 1990 to expand treatments for center failure and other inflammatory conditions. CMO Dr. Eldon R. Smith Editor-in-Chief of the Canadian Journal of Cardiology after a long stinging at the University of Calgary as Head of Cardiology and Dean of Medicine.
The company has noted a wealth of clinical evidence suggesting that CBD has anti-inflammatory properties that would possibly be effective in treating inflammation-related center diseases, such as acute myocarditis and center failure. After his own preclinical studies, Cardiol is even more convinced of the prospective price of CBD. The company presents patented subcutaneous formulas for the bioavailability of CBD.
Cardiol has shaped a number of clinical trials to examine CBD as a remedy for acute myocarditis (phase 1 introduced in August 2020) and center failure. Along the way, the company discovered the link between cardiovascular disease and the serious effects of COVID-19. patent in early May 2020 to protect “the management of CBD to decrease the severity of the disease in patients with COVID-19 with pre-existing cardiovascular diseases and to prevent the progression of such conditions”.
The Phase II / III trial of Cardiol will be conducted in primary centers in the United States, where the prevalence of COVID-19 remains high, and will be monitored through an independent committee, comprised of an impressive collection of experts in inflammatory center diseases: Dr. Dennis McNamara (chair), professor of medicine and director of the transplant / failure program at the University of Pittsburgh center; Dr. Leslie Cooper (Co-Chair), Chair of the Mayo Clinic Enterprise Department of Cardiovascular Medicine and Chair of the Mayo Clinic Department of Cardiovascular Medicine; Dr. Arvind Bhimaraj, Medical Director, Advanced Heart Failure, Heart Transplant and Mechanical Circulatory Support Programs, Houston Methodist Hospital; Dr. Barry Trachtenberg, Director, Cardio-Oncology and Cardiac Amyloid Programs, Associate Director, Mechanical Circulatory Support Program, Houston Methodist Hospital; Dr. Wilson Tang, Director of the Center for Clinical Genomics, Director of Research and Staff Cardiologist, Heart Failure and Heart Transplantation Section, Cleveland Clinic; Dr. Peter Liu, Chief Scientific Officer and Vice President for Research, University of Ottawa Heart Institute; Dr. Carsten Tschöpe, Deputy Director of the Department of Cardiology, Medicine at Charité University in Berlin, Germany; Dr. Matthias Friedrich, Professor of Medicine and Chief of Cardiovascular Imaging, McGill University Health Center.
Where you’re headed
The hope is to demonstrate its effectiveness “in preventing cardiovascular and pulmonary headaches in hospitalized patients, with a proven diagnosis of COVID-19 in the last 24 hours, and who have pre-existing CVD and/or significant threat points for CVD”. The successful IND application provides Cardiol with an accelerated regulatory approval procedure that not only shortens the duration of the clinical program from start to finish, but also reduces the prices of a popular clinical program.
Cardiol hopes to launch the test in the fourth trimester with expected effects in the current part of 2021. Along with the company’s Phase I test in Canada, which is expected to be completed until the end of 2020, and intfinishs to assist a foreign Phase II test in The Effectiveness of CbD as a Remedy for Acute Myocarditis, this trial represents a primary prospective catalyst for the company’s inventory in the coming months. At the same time, Cardiol anticipates the imminent launch of its CBD pharmaceutical product in the Canadian market in collaboration with Shoppers Drug Mart, which represents a vital opportunity for advertising profits for the company. Investors may need to watch cardiol therapeutics for more advances as the company extends its multiple sars in the water.
Please link to read the full article: http://www. secfilings. com/news/fda-approves-landmark-covidheartcbd-clinical-trial-174/
About SECFilings. com
Founded in 2004, SECFilings. com provides real-time loose deposit alerts to more than 600,000 registered members.
Warning
SECFilings. com is not a currency investment adviser or an independent stockbroker. You deserve to consult your own independent legal, tax and / or investment professionals before making any investment decisions. The data provided on http://www. secfilings. com (the “Site”) is original monetary news or paid advertising written through our internal team or provided through an affiliate. SECFilings. com, a monetary data media and marketing company, enters into media or service purchase agreements with corporations that are the subject of articles published on the Site or other publishers for corporate advertising. Array We are not an independent news media provider. We do not offer guarantees or representations related to the data, adding its completeness, correctness, veracity or reliability, and we expressly and implicitly waive all guarantees of any kind, adding whether the data is complete, ordered accurate, true or reliable. As such, your use of the data is at your own risk. We do not assume any legal responsibility for updating the parts shown. SECFilings. com has earned the rebate for generating and presenting high-quality, sophisticated content on SECFilings. com, as well as monetary and corporate data.
The previous article is sponsored content. Emerging Growth LLC, owner of SECFilings. com, has been hired to raise awareness. Follow the link below to see our full disclosure of our compensation: http://www. secfilings. com/legal/disclaimer.
Back to the connection